The slide to be stained for
CD5 comprised: 1:
Mantle cell lymphoma, 2-3:
small
lymphocytic lymphoma/CLL, 4-5:
tonsil (fixed for 24 and 96 hours,
respectively, in 10 % neutral buffered
formalin),
6: Burkitt lymphoma.
Criteria for assessing a CD5
staining as optimal included: A strong and distinct membranous
staining of the normal T-cells in the two tonsil specimens, the
neoplastic B-cells of the mantle cell lymphoma and of one of the CLL’s.
The other CLL should give a weak but distinct staining of the
neoplastic cells. In Burkitt’s lymphoma, only the normal T-cells
should react. With clone 4C7 a faint cross reaction with smooth
muscle cells in larger vessels was accepted.
65 laboratories submitted
stainings. At the assessment 25 achieved optimal staining (39 %), 17
good (26 %), 12 borderline (18 %) and 11 (17%) poor staining.

50 laboratories used mAb
clone 4C7, obtained from Novocastra (42 labs.), Ventana (5 labs.)
and NeoMarkers (3 labs.). 15 used mAb clone CD5/54/F6 from
DakoCytomation. Optimal staining could be obtained with both clones.
All laboratories achieving
an optimal staining used HIER, most frequently (22/25) with
Tris-EDTA/EGTA pH 9 as the heating buffer. There was a slight
difference in the reaction patterns of the two clones used. Both
labelled very intensively the normal T-cells in the two tonsil
specimens, but the staining of the mantle cell lymphoma was more
intense and constant using mAb clone 4C7. In the two CLL’s the
reaction patterns with the two clones was identical.
The optimal dilution of
clone 4C7 was 1:25 – 1:200, of clone CD5/54/F6 1:20 – 1:50.
Almost
all laboratories were able to detect CD5 in the normal T-cells, but
the identification
of CD5
in the CLL and the mantle cell lymphoma could only be
obtained in protocols with a high sensitivity.
The most frequent causes of
insufficient stainings were:
-Insufficient HIER – too short efficient
heating time (< 15 min.) and/or use of citrate pH 6
-Too dilute concentration of the primary antibody
-Too high concentration of the primary antibody.
|